Clinical trial
A 52-week (Plus Extension Until Commercialization), Single-arm Study to Evaluate Psoriasis Severity and Its Psychosocial Impact Using the Simplified Psoriasis Index (SPI) at 16 Weeks, as Well as Long-term Safety, Tolerability and Efficacy of Secukinumab A
Evaluate psoriasis severity and its psychosocial impact using a novel Patient Reported Outcome (the Simplified Psoriasis Index SPI) at 16 weeks, as well as long-term safety, tolerability and efficacy of secukinumab administered subcutaneously during 52 weeks (plus extension) in patients with moderate to severe psoriasis.
| Category | Value |
|---|---|
| Date last updated at source | 2016-07-20 |
| Study type(s) | Interventional |
| Expected enrolment | 120 |
| Study start date | 2015-05-01 |
| Estimated primary completion date | 2017-01-01 |